FDA.reportPublic FDA data

AMMONIA

Substance profile for UNII 5138Q19F1X, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for AMMONIA
Structure render from NCI/CADD chemical resolver

Substance Identity#

UNII
5138Q19F1X
Preferred term
AMMONIA
Registry number
7664-41-7
EC number
231-635-3
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
H3N
Chemical structure for AMMONIA
Structure render from NCI/CADD chemical resolver

Chemical And Database Identifiers#

InChIKey
QGZKDVFQNNGYKY-UHFFFAOYSA-N
SMILES
N
RxCUI
1299884
PubChem
0
NCIt
C76698
INN ID
0

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem InChIKey SearchQGZKDVFQNNGYKY-UHFFFAOYSA-Npubchem.ncbi.nlm.nih.gov/#query=QGZKDVFQNNGYKY-UHFFFAOYSA-N
RxNorm1299884mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1299884
NCI ThesaurusC76698ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C76698
FDA Substance Registration System5138Q19F1Xprecision.fda.gov/uniisearch/srs/unii/5138Q19F1X
European Community number231-635-3commonchemistry.cas.org/results?q=231-635-3

DailyMed Socrata Ingredients#

Type, DailyMed label, SPL version table
TypeDailyMed labelSPL version
INACTIVE INGREDIENTLANSOPRAZOLE7
INACTIVE INGREDIENT075dbfb1-47c2-4578-a212-f8e656f0e9f92
INACTIVE INGREDIENTPANTOPRAZOLE SODIUM2
INACTIVE INGREDIENT104fea5c-cb2a-16c3-e054-00144ff88e882
INACTIVE INGREDIENTTEMAZEPAM1
INACTIVE INGREDIENTIndomethacin Extended Release Capsules, USP Rx only2
INACTIVE INGREDIENTESOMEPRAZOLE MAGNESIUM1
ACTIVE MOIETYfc36eaa5-499d-4a96-a144-cffae64878a41
ACTIVE INGREDIENTfc36eaa5-499d-4a96-a144-cffae64878a41
INACTIVE INGREDIENTGABAPENTIN2
INACTIVE INGREDIENTVOLTAREN2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use esomeprazole magnesium safely and effectively. See full prescribing information for esomeprazole magnesium. Esomeprazole magnesium delayed-release capsules USP, for oral use Initial U.S. Approval: 1989 (omeprazole)6
INACTIVE INGREDIENTIndomethacin Capsules USP, 25 mg and 50 mg5
INACTIVE INGREDIENTINDOMETHACIN1
INACTIVE INGREDIENTClearasil ® Ultra™ Rapid Action Clear Skin1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use tacrolimus capsules safely and effectively. See full prescribing information for tacrolimus capsules. TACROLIMUS Capsules, USP for oral use Initial U.S. Approval: 19946
INACTIVE INGREDIENTBENZONATATE CAPSULES, USP Rx Only5
INACTIVE INGREDIENTThese highlights do not include all the information needed to use ziprasidone safely and effectively. See full prescribing information for ziprasidone. ZIPRASIDONE hydrochloride capsules for oral use Initial U.S. Approval: 20013
INACTIVE INGREDIENTOmeprazole DR2
INACTIVE INGREDIENTIndomethacin Extended – Release Capsules, USP 75 mg5
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use omeprazole delayed-release capsules safely and effectively. See full prescribing information for omeprazole delayed-release capsules. OMEPRAZOLE Delayed-Release Capsules USP Initial U.S. Approval: 19895
INACTIVE INGREDIENTThese highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP. OMEPRAZOLE Delayed-Release Capsules, USP, for oral use INITIAL U.S. APPROVAL: 19894
INACTIVE INGREDIENTThese highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP. OMEPRAZOLE Delayed-Release Capsules, USP, for oral use INITIAL U.S. APPROVAL: 19892
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluoxetine capsules safely and effectively. See full prescribing information for fluoxetine capsules. FLUOXETINE capsules, USP for oral use Initial U.S. Approval: 19873
INACTIVE INGREDIENTThese highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE Sodium delayed-release tablets USP for oral use Initial U.S. approval: 20001
INACTIVE INGREDIENTThese highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP . OMEPRAZOLE Delayed-Release Capsules, USP , for oral use INITIAL U.S. APPROVAL: 198915
INACTIVE INGREDIENTDrug Facts3
INACTIVE INGREDIENTNexa ® Plus Capsules1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluoxetine capsules, USP safely and effectively. See full prescribing information for fluoxetine capsules, USP. FLUOXETINE Capsules, USP for Oral Use Initial U.S. Approval: 19874
INACTIVE INGREDIENTf1f051d8-b8d8-4afd-84d8-82a59d9fa4fb1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Omeprazole delayed-release capsules safely and effectively. See full prescribing information for Omeprazole delayed-release capsules. OMEPRAZOLE delayed-release capsules, USP, for oral use Initial U.S. Approval: 198923
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Duloxetine Delayed-release Capsules safely and effectively. See full prescribing information for Duloxetine Delayed-release Capsules. DULOXETINE delayed-release capsules USP for oral use. Initial U.S. Approval: 20042
INACTIVE INGREDIENTThese highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP. OMEPRAZOLE Delayed-Release Capsules, USP, for oral use INITIAL U.S. APPROVAL: 19892
INACTIVE INGREDIENTAfeditab CR (Nifedipine Extended Release Tablets)4
INACTIVE INGREDIENTCEPHALEXIN CAPSULES, USP8
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluoxetine capsules, USP safely and effectively. See full prescribing information for fluoxetine capsules, USP. FLUOXETINE Capsules, USP for Oral Use Initial U.S. Approval: 198715
INACTIVE INGREDIENTERY-TAB (ERYTHROMYCIN DELAYED-RELEASE TABLETS, USP) ENTERIC-COATED ®2
INACTIVE INGREDIENTERY-TAB (ERYTHROMYCIN DELAYED-RELEASE TABLETS, USP) ENTERIC-COATED ®2
ACTIVE MOIETYAller-Detox: Indoor Pollution Control1
ACTIVE INGREDIENTAller-Detox: Indoor Pollution Control1
INACTIVE INGREDIENTRevised: January 2014 Glipizide Extended-Release Tablets For Oral Use Rx only2
ACTIVE INGREDIENTKENALOG ® -40 INJECTION (triamcinolone acetonide injectable suspension, USP)2
ACTIVE MOIETYKENALOG ® -40 INJECTION (triamcinolone acetonide injectable suspension, USP)2
INACTIVE INGREDIENTCLARAVIS™ (isotretinoin capsules USP)4
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Omeprazole safely and effectively. See full prescribing information for Omeprazole. Omeprazole (Omeprazole) CAPSULE for ORAL use. Initial U.S. Approval: 20133
INACTIVE INGREDIENTGabapentin Capsules, USP 100 mg, 300 mg and 400 mg2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use PANTOPRAZOLE SODIUM safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM. PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM) TABLET for ORAL use. Initial U.S. Approval: 20073
INACTIVE INGREDIENTThese highlights do not include all the information needed to use dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP safely and effectively. See full prescribing information for dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP. Dicyclomine hydrochloride capsules USP, for oral use Dicyclomine hydrochloride tablets USP, for oral use Initial U.S. Approval: 19501
INACTIVE INGREDIENTThese highlights do not include all the information needed to use ziprasidone hydrochloride capsules safely and effectively. See full prescribing information for ziprasidone hydrochloride capsules. Ziprasidone Hydrochloride Capsules Initial U.S. Approval: 20014
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. FLUOXETINE capsules USP for oral use Initial U.S. Approval: 19871
INACTIVE INGREDIENTThese highlights do not include all the information needed to use ziprasidone safely and effectively. See full prescribing information for ziprasidone. Ziprasidone Hydrochloride Capsules for Oral use Initial U.S. Approval: 20013
INACTIVE INGREDIENTDrug Facts2
INACTIVE INGREDIENTMEXILETINE HYDROCHLORIDE CAPSULES USP 8739 8740 8741 Rx only2
INACTIVE INGREDIENTDRUG FACTS8
ACTIVE MOIETYDrug Facts6
ACTIVE INGREDIENTDrug Facts6
ACTIVE INGREDIENTDrug Facts3
ACTIVE MOIETYDrug Facts3
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluvastatin capsules safely and effectively. See full prescribing information for fluvastatin capsules. Fluvastatin Capsules, USP for oral use Initial U.S. Approval: 19932
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluvastatin capsules safely and effectively. See full prescribing information for fluvastatin capsules. Fluvastatin Capsules, USP for oral use Initial U.S. Approval: 19932
INACTIVE INGREDIENTThese highlights do not include all the information needed to use dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP safely and effectively. See full prescribing information for dicyclomine hydrochloride capsules, USP and dicyclomine hydrochloride tablets, USP. Dicyclomine hydrochloride capsules USP, for oral use Dicyclomine hydrochloride tablets USP, for oral use Initial U.S. Approval: 19502
INACTIVE INGREDIENTDILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP (Once-a-Day Dosage) Rx Only4
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTMyorisan TM (isotretinoin capsules, USP) 10 mg, 20 mg, 40 mg2
INACTIVE INGREDIENTRanitidine Tablets, USP and Ranitidine Capsules2
INACTIVE INGREDIENTDILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP6
INACTIVE INGREDIENTGlipizide Extended-Release Tablets Rx only4
INACTIVE INGREDIENTTETRACYCLINE HYDROCHLORIDE CAPSULES USP2
INACTIVE INGREDIENTd6a161d9-7e7a-4711-ba0e-c9040c42268d5
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use verapamil hydrochloride extended-release capsules (PM) safely and effectively. See full prescribing information for verapamil hydrochloride extended-release capsules (PM). Verapamil Hydrochloride Extended-release Capsules (PM) (Controlled Onset) for Oral use Initial U.S. Approval: 19982
INACTIVE INGREDIENTb3180408-a3c0-4e02-8535-dea390a522777
INACTIVE INGREDIENTEtodolac Capsules and Tablets, USP2
INACTIVE INGREDIENTTussiCaps ® (Hydrocodone Polistirex and Chlorpheniramine Polistirex) Extended-Release Capsules CIII Rx only1
INACTIVE INGREDIENTd4569486-e581-4671-b32c-1903abfa726e1
INACTIVE INGREDIENTGlytone essentials rejuvenate daily3
INACTIVE INGREDIENTGlytone Essentials rejuvenate daily3
INACTIVE INGREDIENTThese highlights do not include all the information needed to use omeprazole delayed-release capsules safely and effectively. See full prescribing information for omeprazole delayed-release capsules. Omeprazole Delayed-Release Capsules, USP Initial U.S. Approval: 19893
INACTIVE INGREDIENT2ed81194-be24-45a0-8dde-fbc6ad3d7abe4
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19872
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Fluoxetine safely and effectively. See full prescribing information for Fluoxetine. Fluoxetine capsules for oral use Initial U.S. Approval: 19871
INACTIVE INGREDIENTFULL PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE. OMEPRAZOLE DELAYED-RELEASE (omeprazole) capsule, delayed release for oral use Initial U.S. Approval: 19893
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Voltaren® Gel safely and effectively. See full prescribing information for Voltaren® Gel. Initial U.S. Approval: 19885
INACTIVE INGREDIENTThese highlights do not include all the information needed to use REYATAZ safely and effectively. See full prescribing information for REYATAZ. REYATAZ ® (atazanavir sulfate) Capsules Initial U.S. Approval: 20032
INACTIVE INGREDIENTe69fa3b1-f8eb-4289-bc79-f40f25cfa4181
INACTIVE INGREDIENTAmoxicillin Capsules, Tablets and Powder for Oral Suspension, USP6
INACTIVE INGREDIENTDronabinol Capsules, USP CIII Rx only3
INACTIVE INGREDIENTRIFAMPIN CAPSULES, USP2
INACTIVE INGREDIENTIndomethacin Capsules USP, 25 mg and 50 mg3
INACTIVE INGREDIENTLithium Carbonate Capsules USP Rx Only6
INACTIVE INGREDIENTIndomethacin Extended – Release Capsules, USP 75 mg3231
INACTIVE INGREDIENTNeomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution USP (Sterile)3
INACTIVE INGREDIENTNatural Advantage SPF 15 All Day Moisture with AHAs2
INACTIVE INGREDIENTRX Only1
INACTIVE INGREDIENTGFS BIOPROTECT ALOE VERA HAND SANITIZER-ALCOHOL FREE-GEL8
INACTIVE INGREDIENTThese highlights do not include all the information needed to use tamsulosin hydrochloride capsules safely and effectively. See full prescribing information for tamsulosin hydrochloride capsules. Tamsulosin Hydrochloride Capsules, 0.4 mg Initial U.S. Approval: 19973
INACTIVE INGREDIENTThese highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19879
INACTIVE INGREDIENTRIFAMPIN CAPSULES, USP2
INACTIVE INGREDIENTStrazepam17
INACTIVE INGREDIENTFluoxetine 10 mg These highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19879
INACTIVE INGREDIENTFluoxetine 10 mg These highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. Initial U.S. Approval: 19878
INACTIVE INGREDIENTThese highlights do not include all the information needed to use tamsulosin hydrochloride safely and effectively. See full prescribing information for tamsulosin hydrochloride. Tamsulosin Hydrochloride Capsules USP*, 0.4 mg Initial U.S. Approval: 19971
INACTIVE INGREDIENTDILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP2
INACTIVE INGREDIENTIndomethacin Capsules USP, 25 mg2
INACTIVE INGREDIENTSKIN EFFECTS BY DR. JEFFREY DOVER GLYCOLIC DAY CREAM SPF 3010
INACTIVE INGREDIENTGlytone Retexturize Body2
INACTIVE INGREDIENTDrug Facts2
INACTIVE INGREDIENTLithium Carbonate Capsules USP Rx Only4
INACTIVE INGREDIENTLithium Carbonate Capsules USP Rx Only2
INACTIVE INGREDIENTERY-TAB® (erythromycin delayed-release tablets, USP) ENTERIC-COATED1
INACTIVE INGREDIENT3bb441fb-3c40-45d6-bb10-c761cc8e83b02
INACTIVE INGREDIENTLithium Carbonate Capsules USP 150 mg, 300 mg and 600 mg2
INACTIVE INGREDIENTDILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP1
INACTIVE INGREDIENTRifampin Capsules, USP1
INACTIVE INGREDIENT4b5513c3-b57f-46f1-9855-dad1063aa4c92
INACTIVE INGREDIENT322513fd-6be0-4cd9-a0ea-7e4b5b5783362
INACTIVE INGREDIENTLithium Carbonate Capsules USP 150 mg, 300 mg and 600 mg2
INACTIVE INGREDIENT61bf535a-3ed5-4c50-b285-6dcee0624c2d2
INACTIVE INGREDIENTTEMAZEPAM CAPSULE [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]3945

Inactive Ingredient Database#

Browse recovered IID releases and source provenance.

Current IID rows for UNII 5138Q19F1X page 1 of 1 · 14 matching rows.

Ingredient, UNII, CAS table
IngredientUNIICASDosage formRoutePotencyMaximum daily exposure
AMMONIA SOLUTION5138Q19F1X8007576INJECTIONINTRAVENOUS0.22 %w/v
AMMONIA SOLUTION5138Q19F1X8007576SOLUTIONOPHTHALMICADJ PH
AMMONIA SOLUTION5138Q19F1X8007576CAPSULEORAL0.01 mg
AMMONIA SOLUTION5138Q19F1X8007576CAPSULE, DELAYED RELEASEORAL2 mg
AMMONIA SOLUTION5138Q19F1X8007576CAPSULE, EXTENDED RELEASEORALNA
AMMONIA SOLUTION5138Q19F1X8007576SUSPENSIONORALNA
AMMONIA SOLUTION5138Q19F1X8007576TABLETORALNA
AMMONIA SOLUTION5138Q19F1X8007576TABLET, DELAYED RELEASEORALNA
AMMONIA SOLUTION5138Q19F1X8007576TABLET, EXTENDED RELEASEORAL6 mg
AMMONIA SOLUTION5138Q19F1X8007576INJECTIONSUBCUTANEOUSADJ PH
AMMONIA SOLUTION5138Q19F1X8007576FILMSUBLINGUALNA
AMMONIA SOLUTION5138Q19F1X8007576CREAMTOPICAL5.72 %w/w
AMMONIA SOLUTION5138Q19F1X8007576GELTOPICAL1.2 %w/w
AMMONIA SOLUTION5138Q19F1X8007576LOTIONTOPICALADJ PH